Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy (Nature Communications (2017) 8 (14454) DOI: 10.1038/ncomms14454);Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Nature Communications

Volumn 8, Issue , 2017, Pages

  Bengtsson, Niclas E ^a   Hall, John K ^a   Odom, Guy L ^a   Phelps, Michael P ^a   Andrus, Colin R ^a   Hawkins, R David ^a   Hauschka, Stephen D ^a,b   Chamberlain, Joel R ^a   Chamberlain, Jeffrey S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; DYSTROPHIN; GUIDE RNA; BACTERIAL PROTEIN; CAS9 ENDONUCLEASE STREPTOCOCCUS PYOGENES; ENDONUCLEASE;

DISEASE TREATMENT; GENE EXPRESSION; GENETIC ENGINEERING; HOMOLOGY; MUSCLE; MUTATION; NERVOUS SYSTEM DISORDER; PHYSIOLOGICAL RESPONSE; RECOMBINATION; RNA; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DRUG DELIVERY SYSTEM; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE CASSETTE; GENE DELETION; GENE EDITING; GENE EXPRESSION; GENE MUTATION; HOMOLOGOUS RECOMBINATION; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; SKELETAL MUSCLE; ANIMAL; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION; NEUROMUSCULAR DISEASE; PROCEDURES; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; BACTERIAL PROTEINS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DYSTROPHIN; ENDONUCLEASES; GENE EDITING; GENETIC THERAPY; GENETIC VECTORS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; MYOCARDIUM; NEUROMUSCULAR DISEASES; RNA, GUIDE; SEQUENCE DELETION;

EID: 85012887817     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16007     Document Type: Erratum

References (44)

1. Emery, A. E. H. & Muntoni, F. Duchenne Muscular Dystrophy 3rd edn, (Oxford Univ. Press, 2003).
2. Mendell, J. R. et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71, 304-313 (2012).
3. Batchelor, C. L. & Winder, S. J. Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. Trends Cell. Biol. 16, 198-205 (2006).
4. Ervasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G. & Campbell, K. P. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319 (1990).
5. Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adenoassociated viral vectors. Nat. Med. 10, 828-834 (2004).
6. Bengtsson, N. E., Seto, J. T., Hall, J. K., Chamberlain, J. S. & Odom, G. L. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum. Mol. Genet. 25, R9-R17 (2015).
7. Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320-329 (2007).
8. Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261 2002
9. Rahimov, F. & Kunkel, L. M. The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J. Cell Biol. 201, 499-510 (2013).
10. Banks, G. B., Judge, L. M., Allen, J. M. & Chamberlain, J. S. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958 (2010).
11. Lai, Y. et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624-635 (2009).
12. Ousterout, D. G. et al. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 6, 6244 (2015).
13. Li, H. L. et al. Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep. 4, 143-154 (2015).
14. Long, C. et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184-1188 (2014).
15. Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407-411 (2016).
16. Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403-407 2016
17. Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400-403 (2016).
18. Sicinski, P. et al. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244, 1578-1580 (1989).
19. Koenig, M. et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498-506 (1989).
20. Im, W. B. et al. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum. Mol. Genet. 5, 1149-1153 (1996).
21. Flanigan, K. M. et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort. Hum. Mutat. 30, 1657-1666 (2009).
22. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
23. Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186-191 (2015).
24. Himeda, C. L., Chen, X. & Hauschka, S. D. Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles. Methods Mol. Biol. 709, 3-19 (2011).
25. Hartigan-O'Connor, D., Kirk, C. J., Crawford, R., Mule, J. J. & Chamberlain, J. S. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol. Ther. 4, 525-533 (2001).
26. Hu, C. et al. Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice. Mol. Ther. 22, 1792-1802 (2014).
27. Abmayr, S. & Chamberlain, J. S. in Molecular Mechanisms of Muscular Dystrophies (ed. Winder, S. J.) (Landes Bioscience, 2006).
28. Ito, T., Takeshima, Y., Sakamoto, H., Nakamura, H. & Matsuo, M. Purine-rich exon sequences are not necessarily splicing enhancer sequence in the dystrophin gene. Kobe J. Med. Sci. 47, 193-202 (2001).
29. Chamberlain, J. S., Jaynes, J. B. & Hauschka, S. D. Regulation of creatine kinase induction in differentiating mouse myoblasts. Mol. Cell. Biol. 5, 484-492 (1985).
30. Jaynes, J. B., Chamberlain, J. S., Buskin, J. N., Johnson, J. E. & Hauschka, S. D. Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Mol. Cell. Biol. 6, 2855-2864 (1986).
31. Hauser, M. A. et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol. Ther. 2, 16-25 (2000).
32. Odom, G. L., Gregorevic, P., Allen, J. M. & Chamberlain, J. S. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol. Ther. 19, 36-45 (2011).
33. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat. Biotechnol. 33, 538-542 (2015).
34. Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759-771 (2015).
35. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
36. Arnett, A. L. H. et al. Adeno-associated viral vectors do not efficiently target muscle satellite cells. Mol. Ther. Methods Clin. Dev. 1, 14038 (2014).
37. Neri, M. et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord. 17, 913-918 (2007).
38. Phelps, S. F. et al. Expression of full-length and truncated dystrophin minigenes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258 (1995).
39. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
40. Blankinship, M. J. et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10, 671-678 (2004).
41. Takashima, A. Establishment of fibroblast cultures. Curr. Protoc. Cell Biol. 2. 1, 2. 1. 1-2. 1. 12 (2001).
42. Pinello, L. et al. Analyzing CRISPR genome-editing experiments with CRISPResso. Nat. Biotechnol. 34, 695-697 (2016).
43. Dellorusso, C., Crawford, R. W., Chamberlain, J. S. & Brooks, S. V. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22, 467-475 (2001).
44. Gregorevic, P. et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787-789 2006